Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema
NCT ID: NCT00571142
Last Updated: 2024-05-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
20 participants
INTERVENTIONAL
2007-11-30
2008-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema
NCT00417716
Bevacizumab and Retinal Vascular Occlusions
NCT00347711
Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation
NCT00804206
Intravitreal Bevacizumab vs Photocoagulation for Proliferative Diabetic Retinopathy
NCT00347698
Intravitreal Bevacizumab for Diabetic Retinopathy
NCT00600262
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Renal disease
Bevacizumab + Pars plana vitrectomy
2.5 mg / 0.1 ml bevacizumab after pars plana vitrectomy. Limitorexis would be optional.
2
Without renal disease
Bevacizumab + pars plana vitrectomy
2.5 mg /0.1 ml of bevacizumab after pars plana vitrectomy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bevacizumab + Pars plana vitrectomy
2.5 mg / 0.1 ml bevacizumab after pars plana vitrectomy. Limitorexis would be optional.
Bevacizumab + pars plana vitrectomy
2.5 mg /0.1 ml of bevacizumab after pars plana vitrectomy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diffuse diabetic macular edema with or without previous treatment
Exclusion Criteria
* Pregnancy
25 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Asociación para Evitar la Ceguera en México
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Asociacion para Evitar la Ceguera en Mexico I.A.P.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Veronica Kon-Jara, MD
Role: PRINCIPAL_INVESTIGATOR
Asociación para Evitar la Ceguera en México
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asociacion para Evitar la Ceguera en Mexico I.A.P.
México, , Mexico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APEC-ret
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.